Taro Pharmaceutical Industries Ltd. (NYSE:TARO) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Saturday.

TARO has been the topic of a number of other reports. TheStreet lowered shares of Taro Pharmaceutical Industries from a “b-” rating to a “c” rating in a report on Thursday, June 15th. Credit Suisse Group lowered shares of Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a report on Tuesday, May 23rd.

Taro Pharmaceutical Industries (NYSE:TARO) traded down 0.58% during trading on Friday, hitting $104.95. 53,370 shares of the stock traded hands. Taro Pharmaceutical Industries has a one year low of $92.28 and a one year high of $124.52. The company has a market capitalization of $4.25 billion, a P/E ratio of 10.69 and a beta of 0.65. The company’s 50 day moving average is $106.84 and its 200 day moving average is $112.23.

COPYRIGHT VIOLATION NOTICE: “Taro Pharmaceutical Industries Ltd. (TARO) Stock Rating Upgraded by BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/09/taro-pharmaceutical-industries-ltd-taro-stock-rating-upgraded-by-bidaskclub.html.

Hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN increased its stake in Taro Pharmaceutical Industries by 11.2% in the 2nd quarter. Wells Fargo & Company MN now owns 1,685 shares of the company’s stock valued at $189,000 after buying an additional 170 shares during the last quarter. Bessemer Group Inc. increased its stake in Taro Pharmaceutical Industries by 138.6% in the 2nd quarter. Bessemer Group Inc. now owns 2,083 shares of the company’s stock valued at $234,000 after buying an additional 1,210 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Taro Pharmaceutical Industries in the 2nd quarter valued at $234,000. Bank of Montreal Can increased its stake in Taro Pharmaceutical Industries by 7.5% in the 2nd quarter. Bank of Montreal Can now owns 2,128 shares of the company’s stock valued at $238,000 after buying an additional 149 shares during the last quarter. Finally, Highstreet Asset Management Inc. acquired a new stake in Taro Pharmaceutical Industries in the 2nd quarter valued at $244,000. Hedge funds and other institutional investors own 14.24% of the company’s stock.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.